EUVIMEDEUVIMED entdecken
Open Access

IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma

Arnold Bolomsky, Michele Ceribelli, Sebastian Scheich, Kristina Rinaldi, Da Wei Huang, Papiya Chakraborty, Lisette Pham, George W Wright, Tony Hsiao, Vivian Morris, Jaewoo Choi, James D Phelan und 9 weitere

Cancer Cell · 2024-07 · 42 (7) · 1185-1201.e14

DOI: 10.1016/j.ccell.2024.05.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024-07. Verfasst von Arnold Bolomsky und 20 weiteren Autor:innen. Beteiligte Einrichtung: Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Interferon Regulatory Factors, Transcription Factors, DNA-Binding Proteins. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Cancer Institute, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) is an incurable plasma cell malignancy that exploits transcriptional networks driven by IRF4. We employ a multi-omics approach to discover IRF4 vulnerabilities, integrating functional genomics screening, spatial proteomics, and global chromatin mapping. ARID1A, a member of the SWI/SNF chromatin remodeling complex, is required for IRF4 expression and functionally associates with IRF4 protein on chromatin. Deleting Arid1a in activated murine B cells disrupts IRF4-dependent transcriptional networks and blocks plasma cell differentiation. Targeting SWI/SNF activity leads to rapid loss of IRF4-target gene expression and quenches global amplification of oncogenic gene expression by MYC, resulting in profound toxicity to MM cells. Notably, MM patients with aggressive disease bear the signature of SWI/SNF activity, and SMARCA2/4 inhibitors remain effective in immunomodulatory drug (IMiD)-resistant MM cells. Moreover, combinations of SWI/SNF and MEK inhibitors demonstrate synergistic toxicity to MM cells, providing a promising strategy for relapsed/refractory disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaInterferon Regulatory FactorsTranscription FactorsDNA-Binding ProteinsPlasma CellsAnimalsHumansMiceGene Expression Regulation, NeoplasticCell Line, TumorCell DifferentiationInterferon Regulatory Factor-4

Stichwörter der Autor:innen

ARID1ACRISPRIRF4MYCSWI/SNFmultiple myelomaplasma cellproteogenomicsproteomicstranscription

Substanzen

Interferon Regulatory FactorsTranscription FactorsDNA-Binding ProteinsInterferon Regulatory Factor-4ARID1A protein, humanArid1a protein, mouse

Autor:innen und Institutionen

  • Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20892, USA.
  • Biometric Research Branch, DCTD, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Protein Mass Spectrometry Group, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21701, USA.
  • Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Förderung

  • Intramural NIH HHS
  • National Cancer Institute
  • National Center for Advancing Translational Sciences
  • National Institutes of Health

Zitieren

APA

Bolomsky, A., Ceribelli, M., Scheich, S., Rinaldi, K., Huang, D. W., Chakraborty, P., Pham, L., Wright, G. W., Hsiao, T., Morris, V., Choi, J., Phelan, J. D., Holewinski, R. J., Andresson, T., Wisniewski, J., Riley, D., Pittaluga, S., Hill, E., Thomas, C. J., …, & Young, R. M. (2024). IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer Cell, 42(7), 1185-1201.e14. https://doi.org/10.1016/j.ccell.2024.05.026

Vancouver

Bolomsky A, Ceribelli M, Scheich S, Rinaldi K, Huang DW, Chakraborty P, et al. IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer Cell. 2024;42(7):1185-1201.e14. doi:10.1016/j.ccell.2024.05.026

BibTeX
@article{Bolomsky2024,
  author = {Bolomsky, Arnold and Ceribelli, Michele and Scheich, Sebastian and Rinaldi, Kristina and Huang, Da Wei and Chakraborty, Papiya and Pham, Lisette and Wright, George W and Hsiao, Tony and Morris, Vivian and Choi, Jaewoo and Phelan, James D and Holewinski, Ronald J and Andresson, Thorkell and Wisniewski, Jan and Riley, Deanna and Pittaluga, Stefania and Hill, Elizabeth and Thomas, Craig J and Muppidi, Jagan and Young, Ryan M},
  title = {IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {7},
  pages = {1185--1201.e14},
  doi = {10.1016/j.ccell.2024.05.026}
}
Kostenlos starten →